The FDA recorded a supplemental approval on 2 October 2026 for pirtobrutinib (NDA 216059), the non-covalent BTK inhibitor used in B-cell malignancies.
The FDA database entry does not state what the supplement covers. Supplements can range from labelling and manufacturing changes to new indications, and without the label text it is not possible to say which this is. Clinicians should check the updated prescribing information before assuming any change in indication.
In India, pirtobrutinib's regulatory status with CDSCO is not given in this record and is unknown here.
- Check the updated FDA label for pirtobrutinib before assuming a new indication.
- Continue current practice until the content of the supplement is known.
- Note that the record lists an approval date only, not a new safety finding.
- Review pirtobrutinib interactions with strong CYP3A inhibitors and inducers as per the existing label.
Why it matters
A supplement can mean anything from a wording change to a new indication; the label decides.
Don't overread it
A licence supplement is not necessarily a new indication.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for oncology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free